David Geer Talks Tech
<$BlogItemFeedLinks$>
Sunday, August 19, 2007
Precisely identifying chemical and nerve agent diseases Courtesy of http://www.geercom.com.
Welcome!
With concerns over exposure to chemical agents and nerve-affecting agents heightened, the demand for accurate infection testing has risen. In response, a new portable test based on biomarkers is being developed that can determine whether a person is ill from exposure.
The tester, or biosensor, which looks like a combination of a pregnancy test and a cholesterol level blood test strip will increase its sensitivity levels many-fold, thanks to researchers at the Pacific Northwest National Laboratory (PNNL). The biosensor will test individual blood and saliva.
Disease that results from nerve and chemical agents produces biomarkers, an identifiable alteration of the protein makeup. The researchers are developing a bridge between the protein evidence and the tester. The bridge will increase the detection of protein changes.
The bridge is a nanoparticle identifier, which takes test results beyond positive and negative to precisely identify disease. It does this by turning the protein evidence into electrochemical evidence.
In this process, the antibody or protein of a disease is used to attract the specific disease’ biomarker. Researchers are adding a nanoparticle label to an additional antibody to better read the biomarker.
By taking a nano-level protein particle called ferrin and extracting its iron content, researchers are turning it into a biomarker trap called apoferritin. The researchers fill the apoferritin with a different metal. By attaching this antibody to the existing antibody, the human body’s immune response antibody becomes electro active.
This increases the electrochemical signal many-fold by hundreds of times, increasing the precision of detection of the specific disease.
Best Regards,
David Geer
Geer Communications
Welcome!
With concerns over exposure to chemical agents and nerve-affecting agents heightened, the demand for accurate infection testing has risen. In response, a new portable test based on biomarkers is being developed that can determine whether a person is ill from exposure.
The tester, or biosensor, which looks like a combination of a pregnancy test and a cholesterol level blood test strip will increase its sensitivity levels many-fold, thanks to researchers at the Pacific Northwest National Laboratory (PNNL). The biosensor will test individual blood and saliva.
Disease that results from nerve and chemical agents produces biomarkers, an identifiable alteration of the protein makeup. The researchers are developing a bridge between the protein evidence and the tester. The bridge will increase the detection of protein changes.
The bridge is a nanoparticle identifier, which takes test results beyond positive and negative to precisely identify disease. It does this by turning the protein evidence into electrochemical evidence.
In this process, the antibody or protein of a disease is used to attract the specific disease’ biomarker. Researchers are adding a nanoparticle label to an additional antibody to better read the biomarker.
By taking a nano-level protein particle called ferrin and extracting its iron content, researchers are turning it into a biomarker trap called apoferritin. The researchers fill the apoferritin with a different metal. By attaching this antibody to the existing antibody, the human body’s immune response antibody becomes electro active.
This increases the electrochemical signal many-fold by hundreds of times, increasing the precision of detection of the specific disease.
Best Regards,
David Geer
Geer Communications
Labels: agent, biomarker, chemical, disease, illness, infection, nerve
